Skip to main content
Have a personal or library account? Click to login
Retrospective Study of Genetic Diversity of Acinetobacter Baumannii-Resistant Strains Isolated from Patients in Rīga East University Hospital in Latvia Cover

Retrospective Study of Genetic Diversity of Acinetobacter Baumannii-Resistant Strains Isolated from Patients in Rīga East University Hospital in Latvia

Open Access
|May 2021

References

  1. Adams, M. D., Chan, E. R., Molyneaux, N. D., Bonomo, R. A. (2010). Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother.,54 (9), 3569–3577.10.1128/AAC.00057-10293497120530228
  2. Anonymous (2016a). Carbapenem-resistant Acinetobacter baumannii in healthcare settings. European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-carbapenem-resistant-acinetobacter-baumannii-healthcare (accessed 12.04.2021).
  3. Anonymous (2016b). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. European Centre for Disease Prevention and Control, Stockholm. https://www.ecdc.europa.eu/en/publications-data/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-3 (accessed 12.04.2021).
  4. Anonymous (2016c). Surveillance Atlas of Infectious Diseases — Antimicrobial resistance. https://ecdc.europa.eu/en/antimicrobial-resistance/surveil-lance-and-disease-data/data-ecdc (accessed 12.04.2021).
  5. Anonymous (2017). WHO publishes list of bacteria for which new antibiotics are urgently needed.http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed 12 April 2021).
  6. Bouvet, P. J., Grimont, P. A. (1986). Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsonii sp. nov. and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwofii. Int. J. Syst. Bacteriol.,36 (2), 228–240.10.1099/00207713-36-2-228
  7. Brossard, K. A., Campagnari, A. A. (2012). The Acinetobacter baumannii biofilm-associated protein plays a role in adherence to human epithelial cells. Infect. Immun.,80 (1), 228–233.10.1128/IAI.05913-11325568422083703
  8. Chen, L., Zheng, D., Liu, B., Yang, J., Jin, Q. (2016). VFDB 2016: Hierarchical and refined dataset for big data analysis —10 years on. Nucl. Acids Res.,44, D694–D697.10.1093/nar/gkv1239470287726578559
  9. Diancourt, L., Passet, V., Nemec, A., Dijkshoorn, L., Brisse, S. (2010). The population structure of Acinetobacter baumannii: Expanding multi-resistant clones from an ancestral susceptible genetic pool. PLoS One., 5 (4), e10034.10.1371/journal.pone.0010034285092120383326
  10. Perez, F. Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.,51 (10) 3471–3484.10.1128/AAC.01464-06204329217646423
  11. Fishbain, J., Peleg, A. Y. (2010). Treatment of Acinetobacter infections. Clin. Infect. Dis.,51 (1), 79–84.10.1086/65312020504234
  12. Fitzpatrick, M. A., Ozer, E. A, Hauser, A. R. (2016). Utility of whole genome sequencing in characterizing Acinetobacter epidemiology and analyzing hospital outbreaks. J. Clin. Microbiol.,54, 593–612.10.1128/JCM.01818-15476797226699703
  13. Fournier, P. E., Richet, H. (2006). The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis.,42 (5), 692–699.10.1086/50020216447117
  14. Gramatniece, A., Silamikelis, I., Zahare, I., Urtans, V., Zahare, I., Dimina, E., Saule, M., Balode, M., Radovica-Spalvina, I., Klovins, J., Fridmanis, D., Dumpis, U. (2019). Control of Acinetobacter baumannii outbreak in the neonatal intensive care unit in Latvia: Whole-genome sequencing powered investigation and closure of the ward. Antimicrob. Resist. Infect. Control,8, 84.10.1186/s13756-019-0537-z653225631143444
  15. Higgins, P. G., Prior, K., Harmsen, D., Seifert, H. (2017). Development and evaluation of a core genome multilocus typing scheme for whole-genome sequence-based typing of Acinetobacter baumannii. PLoS ONE., 12, e0179228.10.1371/journal.pone.0179228546462628594944
  16. Jünemann, S., Sedlazeck, F. J., Prior, K., Albersmeier, A., John, U., Kalinowski, J., Mellmann, A., Goesmann, A., Haeseler, A. von, Stoye, J., Harmsen, D. (2013). Updating benchtop sequencing performance comparison. Nat. Biotechnol.,31 (4), 294–296.10.1038/nbt.252223563421
  17. Kanafani, Z. A., Souha, S. K. (2021). Acinetobacter infection: Epidemiology, microbiology, pathogenesis, clinical features, and diagnosis. https://www.uptodate.com/contents/acinetobacter-infection-epidemiology-microbiology-pathogenesis-clinical-features-and-diagnosis (accessed 12.04.2021).
  18. Kim, S. J., Kim, Y.-J., Ko, K. S., (2018). Genomic analysis of consecutive Acinetobacterbumanii strains from a single patient. Front Microbiol., 9, 2840.10.3389/fmicb.2018.02840627777530542330
  19. Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae I. K., Kim, Y. B, Cha, C. J. C., Jeong, B. C., Lee, S. H. (2017). Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol.,7, 55.10.3389/fcimb.2017.00055534658828348979
  20. Liepiņš, M., Sīmanis, R., Lejnieks, A. (2016). Decreasing prevalence of multidrug-resistant Acinetobacter Baumannii in Rīga East University Hospital. Proc. Latvian Acad. Sci.,70 (4), 232–236.10.1515/prolas-2016-0037
  21. Maragakis, L. L., Perl, T. M. (2008). Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis.,46 (8), 1254–1263.10.1086/52919818444865
  22. Mazumder, S. A. (2021). Acinetobacter.https://emedicine.medscape.com/article/236891-overview (accessed 8 March 2021).
  23. O’Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.https://www.biomerieuxconnection.com/wp-content/uploads/2018/04/Tackling-Drug-Resistant-Infections-Globally_-Final-Report-and-Recommendations.pdf (accessed 12.04.2021).
  24. Owens, R. C., Jr., Rice, L. (2006). Hospital-based strategies for combating resistance. Clin. Infect. Dis., 42 (Suppl. 4), S173–S181.10.1086/50066416544268
  25. Park, S. Y., Choo, J. Y., Kwon, S. H, Yu, S. N., Lee, E. J., Kim, T. H., Choo, E. J., Jeon, M. H. (2013). Risk factors for mortality in patients with Acinetobacter baumannii bacteremia. Inf. Chemother.,45 (3), 325–330.10.3947/ic.2013.45.3.325384851124396634
  26. Rice, L. B. (2008). Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis.,197 (8), 1079–1081.10.1086/53345218419525
  27. Sefid, F., Rasooli, I., Jahangiri, A., Bazmara, H. (2015). Functional exposed amino acids of BauA as potential immunogen against Acinetobacter baumannii. Acta Biotheor.,63 (2),129–149.10.1007/s10441-015-9251-225840681
  28. Xiao, D., Wang, L., Zhang, D., Xiang, D., Liu, Q., Xing, X. (2017). Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: A retrospective analysis. Exper. Ther. Med.,13 (4), 1630–1633.10.3892/etm.2017.4137537756928413520
  29. Zerbino, D.R., Birney, E. (2008). Velvet: Algorithms for de novo short read assembly using de Bruijn graphs. Genome Res., 18 (5), 821–829.10.1101/gr.074492.107233680118349386
DOI: https://doi.org/10.2478/prolas-2021-0022 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 142 - 148
Submitted on: Jul 22, 2020
Accepted on: Apr 13, 2021
Published on: May 8, 2021
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2021 Māris Liepiņš, Angelika Krūmiņa, Irēna Meistere, Diāna Kosjkina, Juris Ķibilds, Olga Valciņa, Aivars Lejnieks, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.